Vaxil Enters Into a Cooperative Research and Development Agreement With U.S. Army Medical Research Institute of Infectious Di...
October 26 2020 - 11:57AM
VAXIL BIO LTD. (“
Vaxil” or the
“
Company”) (TSX VENTURE: VXL), an innovative
immunotherapy biotech company specializing in cancer and infectious
diseases, is pleased to announce that on October 26, 2020, it has
entered into a cooperative research and development agreement
(CRADA) with USAMRIID under which USAMRIID will test CorVax™ for
its ability to specifically prevent COVID-19 in mice.
Vaxil recently reported that its CorVax™
successfully generated an immune response in the experiment carried
out at the Allergy and Clinical Immunology Unit at the Medical
Research, Infrastructure, and Health Services Fund of the Tel Aviv
Sourasky Medical Center in Israel by Dr. David Hagin. As a result,
the Company is progressing to the next study to test whether this
immune response is specific enough to COVID-19 to provide
protection against the virus in a mouse model.
As scientists and companies race to find
vaccines to prevent COVID-19 infection, some platforms are focused
on mRNA, others on viral vectors, viruses and various subunits.
Vaxil is, to the best of the Company’s knowledge, the only company
working with signal peptides, which offer unique advantages of
efficacy in stimulating a broad immune response while achieving a
suitable safety profile. Vaxil’s signal peptide platform has proven
safety in a phase 1/2a study in oncology.
“The initial immunogenicity data sound
intriguing,” said Dr. Joseph W. Golden, a principal investigator in
USAMRIID’s virology division. “We look forward to evaluating this
vaccine formulation for its potential to protect against SARS-CoV-2
in our mouse models.”
The work to be performed by USAMRIID will be
financed out of the Company’s existing working capital, according
to David Goren, Vaxil’s Chairman and Chief Executive Officer. The
team hopes to secure additional funding for future studies.
“We are pleased to have USAMRIID assess our
potential COVID-19 vaccine,” said Goren. “The work in the US will
support and strengthen the experiments we have already done in
Israel in our in-vivo study. Together, the combined research will
help the Company plan and execute more efficient pre-clinical and
clinical programs.”
The Company is not making any express or implied
claims that it has completed developing or will be successful in
developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech
company focused on its novel approach to targeting prominent cancer
markers and infectious diseases. Its lead product ImMucin™
successfully completed a Phase 1/2 clinical trial in multiple
myeloma for which it received orphan drug status from the FDA and
EMA. The company aims to continue to develop ImMucin™, a COVID-19
and a tuberculosis vaccine / treatment that has demonstrated
promising preliminary results with further preclinical evaluation
planned. Additional indications and mAb candidates are under
evaluation as immuno-oncology and infectious disease treatments
alone and in combination with other treatments.
Vaxil exploits the unique properties of signal
peptide domains on crucial proteins to develop targeted therapies
against cancer targets and infectious disease pathogens. These
signal peptide domains are identified by VaxHit™, Vaxil’s
proprietary bioinformatic approach. These signal peptides induce a
robust T- and B-cell response across wide and varied HLA subtypes,
while acting as true, universal neoantigens. The peptide platform
targets these cells by “educating” or specifically activating the
immune system to recognize and attack the affected cells. In
addition, Vaxil’s mAb platform directly recognizes the target
protein expressed on malignant cells and recruits other elements of
the immune system to lyse those cells.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer: The Company cautions that COVID-19
Vaccine Development is still under early stage research and
development and is not making any express or implied claims that it
has the ability to eliminate the COVID-19 virus at this time. The
TSX Venture Exchange Inc. has in no way passed upon the merits of
the Company and has neither approved nor disapproved the contents
of this press release. This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors - including the
availability of funds, the results of financing efforts, the
results of exploration activities -- that could cause actual
results to differ materially from the Company's expectations are
disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. This press
release does not constitute an offer to sell or a solicitation of
an offer to sell any of the securities described herein in the
United States or elsewhere. These securities have not been, and
will not be, registered in the United States Securities Act of
1933, as amended, or any state securities laws, and may not be
offered or sold in the United States or to U.S. persons unless
registered or exempt therefrom.
About the U.S. Army Medical Research
Institute of Infectious Diseases
For over 50 years, USAMRIID has provided leading
edge medical capabilities to deter and defend against current and
emerging biological threat agents. The Institute is the only
laboratory in the Department of Defense equipped to safely study
highly hazardous viruses requiring maximum containment at Biosafety
Level 4. Research conducted at USAMRIID leads to medical solutions
- vaccines, drugs, diagnostics, information, and training programs
- that benefit both military personnel and civilians. Established
in 1969, the Institute plays a key role as the lead military
medical research laboratory for the Defense Threat Reduction
Agency's Joint Science and Technology Office for Chemical and
Biological Defense. USAMRIID is a subordinate laboratory of the
U.S. Army Medical Research and Development Command. For more
information, visit http://www.usamriid.army.mil.
[The information contained in this press release
does not necessarily reflect the position or the policy of the
Government and no official endorsement should be inferred.]
CONTACT INFORMATIONFor further information
please visit http://vaxil-bio.com/ or contact:David
Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Sep 2023 to Sep 2024